What Is KLOW Peptide? A Plain-English Overview

TL;DR

KLOW peptide is not one molecule. It is four separate research peptides dissolved together in a single vial: KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper-carrying tripeptide studied for skin and hair-follicle effects), BPC-157 (a 15-amino-acid peptide studied in wound and tendon models), and TB-500 (a short fragment of a protein called thymosin beta-4, studied for cell migration and tissue repair).

The standard research vial holds 80 mg total in a 50/10/10/10 split: 50 mg GHK-Cu, 10 mg each of BPC-157, TB-500, and KPV. GHK-Cu dominates by mass because it is the best-studied component for dermal and follicle applications.

Key facts: none of the four is FDA-approved for human use. The blend itself has never been tested in a controlled study. The four components clear the body at different speeds, which is a pharmacokinetic (how the body processes a drug) mismatch inherent to the co-formulation. TB-500 is on the WADA banned list for athletes.

KLOW

KLOW is the trade name (and search term) for the four-peptide co-formulation. It is not an abbreviation — the name does not map to the constituent initials in a direct way. It distinguishes the blend from related research formulations:

• GLOW: the three-peptide version — GHK-Cu + BPC-157 + TB-500. No KPV. KLOW adds the KPV anti-inflammatory channel on top.
• WOLVERINE: a different multi-peptide blend with distinct composition.

KLOW is not a weight-management compound and is not related to GLP-1 / incretin signaling. None of its four constituents is a GLP-1 receptor agonist or an established metabolic weight-loss agent. The blend is studied in the context of soft-tissue repair, dermal biology, and inflammation — not metabolic or weight-management endpoints.

KLOW peptide blend

The KLOW peptide blend is a co-formulation — multiple distinct compounds dissolved at fixed ratios in one vial. They remain separate molecules; they do not react with each other to form a new entity.

Canonical composition (80 mg total):

| Constituent | Mass | CAS | MW (Da) | Role | |---|---|---|---|---| | GHK-Cu | 50 mg | 89030-95-5 | 402.92 | Matrix, copper, hair-follicle | | BPC-157 | 10 mg | 137525-51-0 | 1419.53 | Angiogenic, tissue-repair | | TB-500 | 10 mg | — | 889.02 | Cytoskeletal, cell migration | | KPV | 10 mg | 67727-97-3 | 342.44 | Anti-inflammatory, NF-kappaB |

GHK-Cu accounts for ~62.5% of vial mass and is the dominant component by quantity. No pharmacopeial or FDA-approved KLOW combination product exists.

KLOW stack

Some researchers refer to the KLOW blend as a 'KLOW stack' — four peptides stacked in one vial rather than administered separately. This framing is informal and not a regulatory or scientific term.

The combination rationale is that the four constituents address consecutive or complementary steps in one tissue-repair cascade: KPV suppresses the initial cytokine surge (NF-kappaB/MAPK axis), GHK-Cu shifts fibroblast gene expression toward matrix rebuilding and provides copper for collagen crosslinking, BPC-157 drives angiogenesis via VEGFR2/PI3K/Akt/eNOS to re-vascularize damaged tissue, and TB-500 (via the LKKTET actin-binding motif, and more fully via native thymosin beta-4) accelerates keratinocyte migration and follicle stem-cell mobilization.

The cascade logic is mechanistically plausible but not directly validated: no controlled study has tested whether the four-component co-administration produces a different or superior outcome compared to any single component or any subset.

What the literature attributes to each arm

KPV (anti-inflammatory arm): At nanomolar concentrations, KPV reduces NF-kappaB nuclear import and MAPK signaling in human intestinal epithelial cells and Jurkat T cells, lowers TNF-alpha / IL-6 / IL-1beta / IL-8 secretion, and reduces colitis severity in mice via the PepT1 transporter (Dalmasso 2008) ^[3].

GHK-Cu (matrix and follicle arm): Modulates ~31% of human genes at a ≥50%-change threshold (Pickart & Margolina 2018) ^[5]; increases collagen production with documented skin improvement in placebo-controlled topical trials; plasma GHK declines ~60% between age 20 and 60 (Pickart 2015) ^[4]; stimulates follicle activity in C3H mice (Trachy 1991) ^[9].

BPC-157 (angiogenic arm): Accelerates rat Achilles tendon healing at doses ranging from 10 picogram to 10 microgram per rat IP (Staresinic 2003) ^[2]; first-in-human IV safety pilot: n=2, up to 20 mg, well tolerated (Lee & Burgess 2025) ^[6].

TB-500 / thymosin beta-4 (cytoskeletal and follicle-stem-cell arm): +42% re-epithelialization at 4 days, +61% at 7 days (Malinda 1999) ^[1]; activates follicle bulge stem cells and raises MMP-2 (Philp 2004) ^[8]; stem-cell migration and differentiation pathway confirmed (Philp 2007) ^[12]. All follicle/re-epithelialization data are for full-length thymosin beta-4, not the TB-500 fragment.